TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $69.30M | $58.45M | $41.42M | $29.46M | $18.21M | $15.45M | $8.27M | $4.25M |
| Cost of Revenue | $22.81M | $18.34M | $14.37M | $10.65M | $6.98M | $6.17M | $5.33M | $1.71M |
| Gross Profit | $46.49M | $40.11M | $27.04M | $18.81M | $11.23M | $9.27M | $2.94M | $2.53M |
| Gross Margin | 67.08% | 68.62% | 65.30% | 63.85% | 61.68% | 60.03% | 35.56% | 59.65% |
| Operating Expenses | $80.60M | $84.19M | $66.05M | $48.26M | $36.51M | $28.43M | $20.72M | $19.46M |
| Operating Income | $-34.12M | $-44.08M | $-39.01M | $-29.45M | $-25.27M | $-19.16M | $-17.78M | $-16.92M |
| Operating Margin | -49.23% | -75.40% | -94.18% | -99.96% | -138.77% | -124.06% | -214.91% | -398.68% |
| Net Income | $-37.84M | $-46.66M | $-44.30M | $-33.28M | $-28.79M | $-22.43M | $-21.09M | $-21.33M |
| Net Margin | -54.60% | -79.83% | -106.95% | -112.94% | -158.10% | -145.18% | -254.92% | -502.57% |
| EPS (Basic) | $-1.33 | $-2.04 | $-2.73 | $-2.30 | $-2.23 | $-2.26 | $-3.25 | $-3.29 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |